Skip to main content
Telix Pharmaceuticals Ltd logo

Telix Pharmaceuticals Ltd — Investor Relations & Filings

Ticker · TLX ISIN · AU000000TLX2 ASX Manufacturing
Open in API
Filings indexed 988 across all filing types
Latest filing 2026-05-21 Foreign Filer Report
Country US United States of America
Listing ASX TLX

About Telix Pharmaceuticals Ltd

https://telixpharma.com/

Telix Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals, an approach known as 'theranostics'. The company utilizes targeted radiation to both image and treat various forms of cancer. Its extensive clinical pipeline and portfolio address key areas in oncology, including urologic (prostate and kidney), neurologic (glioma), and musculoskeletal cancers, as well as applications in bone marrow conditioning. Telix has secured global regulatory approvals for its prostate cancer imaging agent and supports its products with a robust global supply, manufacturing, and distribution network. The company is actively engaged in numerous clinical trials worldwide to expand its theranostic platform.

Recent filings

Filing Released Lang Actions
CURRENT REPORT OF FOREIGN ISSUER PURSUANT TO RULES 13A-16 AND 15D-16 AMENDMENTS
Foreign Filer Report
2026-05-21 English
Telix Annual General Meeting Chairman and CEO Addresses 10 pages 332.3KB
AGM Information Classification · 95% confidence The document is an ASX announcement titled “Telix Annual General Meeting Chairman and CEO Addresses,” providing the speeches delivered at the company’s 2025 Annual General Meeting, including the Chairman’s Address and CEO’s Address. It is not a financial report (annual or interim), earnings release, proxy statement, or legal notice, but rather materials shared during the AGM itself. This matches the “AGM Information” category.
2026-05-20 English
Telix Annual General Meeting Presentation 46 pages 2.8MB
AGM Information Classification · 95% confidence The document is a slide deck titled “Annual General Meeting of Shareholders” for Telix Pharmaceuticals, containing Chairman’s and CEO’s addresses, strategic priorities, voting instructions, and other AGM materials. It is clearly presentation material shared at the company’s Annual General Meeting rather than the full annual report or earnings release. Therefore, it meets the definition of AGM Information (AGM-R).
2026-05-20 English
Results of Annual General Meeting 5 pages 224.6KB
Declaration of Voting Results & Voting Rights Announcements Classification · 96% confidence The document is an ASX announcement titled “Telix Results of Annual General Meeting” and provides detailed poll voting outcomes for each resolution at the AGM. It reports the official vote counts and results in line with section 251AA of the Corporations Act. This fits exactly the definition of a Declaration of Voting Results & Voting Rights Announcement (Code: DVA).
2026-05-20 English
App 3X Initial Director Interests - D Gill 2 pages 299.7KB
Director's Dealing Classification · 98% confidence The document is an ASX Appendix 3X “Initial Director’s Interest Notice” disclosing a director’s relevant interests in securities, typical of insider shareholding notifications under Australian listing rules. This corresponds to a Director’s Dealing report.
2026-05-13 English
App 3X Initial Director Interests - M Rivas 2 pages 299.0KB
Director's Dealing Classification · 95% confidence The document is an ASX Appendix 3X “Initial Director’s Interest Notice” under listing rule 3.19A.1, disclosing a director’s relevant interests (securities holdings) upon appointment. This is a statutory insider transaction/interest disclosure by a director, matching the Director’s Dealing category.
2026-05-13 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.